Vtv Theraptcs Cl A (VTVT) Stock Price, Quote & News

Company Profile

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a lic...

Industry: Biotechnology

Sector: Healthcare

Phone: 336 841 0300

Fax: 336 841 0310

Website: vtvtherapeutics.com

Address:

3980 Premier Drive, Suite 310, High Point, United States

GDS_investing Nov. 14 at 2:23 PM

$CDTX great $VTVT or $AGEN is next all for long

1 · Reply

LongBallBarn Nov. 13 at 1:50 PM

$VTVT

0 · Reply

GDS_investing Nov. 13 at 12:32 PM

$VTVT next target 56$ long to 240 and 480$

4 · Reply

GDS_investing Nov. 12 at 6:10 PM

$VTVT Baker Brothers Advisors is the investment adviser for vTv Therapeutics (VTVT) and has a director role at the company. Baker Brothers has reported insider transactions for VTVT, such as purchasing warrants in September 2025. This indicates a close relationship between the investment firm and the biopharmaceutical company. Investment Advisor: Baker Brothers Advisors LP acts as the investment adviser for vTv Therapeutics Inc. (VTVT). Director Role: A representative from Baker Brothers Advisors LP serves on the vTv Therapeutics board of directors. This is often done via "deputization," which means a person is considered a director for reporting purposes even if they are not a formal officer. Insider Transactions: Baker Brothers has been involved in recent insider transactions for VTVT, including the purchase of warrants and pre-funded warrants in September 2025. These transactions are reported to regulatory bodies like the Securities and Exchange Commission.

2 · Reply

GDS_investing Nov. 12 at 6:07 PM

$VTVT Did you know that: "Baker Brothers Advisors (BBA) has a director role and a significant ownership stake in vTv Therapeutics (VTVT), which is a clinical-stage biopharmaceutical company. BBA's involvement is based on its investment strategy of taking large, concentrated, long-term positions in life science companies, and it is listed as the investment adviser to VTVT. Recent insider filings show Baker Brothers Advisors engaging in a "Director deals" transaction involving VTVT, specifically buying a number of shares." LONG and STRONG

1 · Reply

LongBallBarn Nov. 12 at 5:43 PM

$VTVT

0 · Reply

Estockpicker Nov. 12 at 5:13 PM

$VTVT how is it a buy? no real interest because there is no data incoming for along while

1 · Reply

Nova_Trades Nov. 12 at 4:31 AM

Wednesday Watchlist — Pt. 1 $COGT, $QNRX, $VTVT, $FLY, $GEMI watching for breakout continuation with strong volume follow-through. 📊

0 · Reply

Stock_Catcher Nov. 12 at 3:14 AM

Money Wednesday Watchlist Pt. 10 $COGT $VTVT $GEMI $QNRX $FLY Tomorrow should be Crazy after like a 1000% runner. Make sure yall ready. 📈😱

1 · Reply

JimJames Nov. 11 at 10:49 PM

$VTVT

0 · Reply

vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 9, 2025, 8:00 AM EDT - 5 weeks ago

vTv Therapeutics Announces New Appointments to its Scientific Advisory Board

Sep 15, 2025, 8:00 AM EDT - 2 months ago

vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting

Sep 3, 2025, 4:57 PM EDT - 2 months ago

UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences

Sep 3, 2025, 8:00 AM EDT - 2 months ago

vTv Therapeutics to Participate in Upcoming September Investor Conferences

Sep 2, 2025, 8:00 AM EDT - 2 months ago

vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund

Aug 12, 2025, 4:15 PM EDT - 3 months ago

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 11, 2025, 8:00 AM EDT - 3 months ago

vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

Aug 7, 2025, 8:00 AM EDT - 3 months ago

vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes

Jun 11, 2025, 8:00 AM EDT - 5 months ago

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

May 19, 2025, 9:00 AM EDT - 6 months ago

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

May 15, 2025, 4:01 PM EDT - 6 months ago

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

May 15, 2025, 12:00 PM EDT - 6 months ago

vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

Mar 20, 2025, 5:35 PM EDT - 8 months ago

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 17, 2025, 1:59 PM EDT - 8 months ago

FDA Lifts Clinical Hold On vTv Therapeutics' Phase 3 Diabetes Trial, Stock Surges

Mar 17, 2025, 8:30 AM EDT - 8 months ago

vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

Dec 9, 2024, 7:33 AM EST - 1 year ago

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

Dec 2, 2024, 4:05 PM EST - 1 year ago

vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference

Aug 8, 2024, 4:15 PM EDT - 1 year ago

vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

Jul 26, 2024, 4:05 PM EDT - 1 year ago

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

Jun 24, 2024, 4:05 PM EDT - 1 year ago

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes

May 28, 2024, 8:00 AM EDT - 1 year ago

CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING

May 9, 2024, 4:51 PM EDT - 1 year ago

vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update

Mar 19, 2024, 8:30 AM EDT - 1 year ago

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT

Mar 13, 2024, 8:00 AM EDT - 1 year ago

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 4, 2024, 8:00 AM EST - 1 year ago

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

Mar 1, 2024, 8:00 AM EST - 1 year ago

vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference

Feb 28, 2024, 8:00 AM EST - 1 year ago

vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund

Feb 22, 2024, 4:00 PM EST - 1 year ago

CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE

Nov 9, 2023, 4:30 PM EST - 2 years ago

vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update

Nov 8, 2023, 8:00 AM EST - 2 years ago

vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference

Nov 2, 2023, 8:00 AM EDT - 2 years ago

vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer

Nov 1, 2023, 8:00 AM EDT - 2 years ago

vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million

Sep 27, 2023, 8:30 AM EDT - 2 years ago

CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19

$Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer$

Sep 26, 2023, 8:30 AM EDT - 2 years ago

Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer

Sep 18, 2023, 8:30 AM EDT - 2 years ago

CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA

Aug 11, 2023, 4:30 PM EDT - 2 years ago

vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update

Aug 10, 2023, 8:33 AM EDT - 2 years ago

Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer

Jun 16, 2023, 8:00 AM EDT - 2 years ago

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline

Jun 15, 2023, 7:33 AM EDT - 2 years ago

CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON

May 24, 2023, 9:00 AM EDT - 2 years ago

vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals

May 11, 2023, 4:15 PM EDT - 2 years ago

vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update

Apr 20, 2023, 8:00 AM EDT - 2 years ago

Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19

Mar 6, 2023, 5:56 PM EST - 2 years ago

vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 6, 2023, 8:02 AM EST - 2 years ago

Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases

Feb 27, 2023, 8:02 AM EST - 2 years ago

Cantex Receives FDA "Study May Proceed" Letter for Phase 2 Clinical Trial of Azeliragon for the Treatment of Unmethylated Glioblastoma

Feb 1, 2023, 5:00 PM EST - 3 years ago

Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics

Jan 9, 2023, 8:00 AM EST - 3 years ago

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF GLIOBLASTOMA

Dec 13, 2022, 8:15 AM EST - 3 years ago

vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer

Nov 10, 2022, 5:25 PM EST - 3 years ago

vTv Therapeutics Announces 2022 Third Quarter Financial Results and Provides Corporate Update

GDS_investing Nov. 14 at 2:23 PM

$CDTX great $VTVT or $AGEN is next all for long

1 · Reply

LongBallBarn Nov. 13 at 1:50 PM

$VTVT

0 · Reply

GDS_investing Nov. 13 at 12:32 PM

$VTVT next target 56$ long to 240 and 480$

4 · Reply

GDS_investing Nov. 12 at 6:10 PM

2 · Reply

GDS_investing Nov. 12 at 6:07 PM

1 · Reply

LongBallBarn Nov. 12 at 5:43 PM

$VTVT

0 · Reply

Estockpicker Nov. 12 at 5:13 PM

$VTVT how is it a buy? no real interest because there is no data incoming for along while

1 · Reply

Nova_Trades Nov. 12 at 4:31 AM

Wednesday Watchlist — Pt. 1 $COGT, $QNRX, $VTVT, $FLY, $GEMI watching for breakout continuation with strong volume follow-through. 📊

0 · Reply

Stock_Catcher Nov. 12 at 3:14 AM

Money Wednesday Watchlist Pt. 10 $COGT $VTVT $GEMI $QNRX $FLY Tomorrow should be Crazy after like a 1000% runner. Make sure yall ready. 📈😱

1 · Reply

JimJames Nov. 11 at 10:49 PM

$VTVT

0 · Reply

JohnWick0 Nov. 11 at 10:49 PM

$VTVT 👀🔥

0 · Reply

Samiam69 Nov. 11 at 10:13 PM

$VTVT https://www.zacks.com/stock/news/2789481/all-you-need-to-know-about-vtv-therapeutics-vtvt-rating-upgrade-to-buy?cid=CS-STOCKTWITS-HL-tale_of_the_tape%7Cyseop_template_12_zacks_rank_upgrade-2789481&adid=SYND_STOCKTWITS_HEADLINE_TALEOFTHETAPE_523_2789481 🐢🐢🐢⏳⌛️⏳⌛️⏳⌛️

0 · Reply

Estockpicker Nov. 11 at 7:16 PM

$VTVT it’s lucky that a few people have been able to get out. Still super low volume. Big sell off is coming.

2 · Reply

Estockpicker Nov. 11 at 7:15 PM

$VTVT buy the dip when they release financials. Think about it. They make zero money and they will be adding millions and millions of shares.

1 · Reply

dcajic2 Nov. 11 at 6:16 PM

$VTVT Up on what??? Where is the news???? Extremely low trading volume. They are. along way off from giving any information with regard to data. This company barely ever gives any information

0 · Reply

KeeperOfHollowCharts Nov. 11 at 6:13 PM

$VTVT Window is Nov 11 to 13 and today qualifies. NXXT backed by Barclays 32,840 and UBS 43,870. Undervalued now and likely repriced on the print. Entry window is open

0 · Reply

vihaanmuellerr Nov. 11 at 5:55 PM

$VTVT Earnings alert today. NXXT seeing steady accumulation. Vanguard 1,049,265 and NY State Common 28,100. Smart money preparing for the print

0 · Reply

Samiam69 Nov. 11 at 5:33 PM

$VTVT 50 soon possible 🐢🐢💰💰

0 · Reply

LongBallBarn Nov. 11 at 4:43 PM

$VTVT $TGE $DOMH $EPOW

0 · Reply

JohnWick0 Nov. 11 at 4:42 PM

$VTVT

0 · Reply

topstockalerts Nov. 11 at 4:35 PM

$VTVT looking bouncy..

0 · Reply

MakennaCipher Nov. 11 at 4:19 PM

$VTVT Strong print → upgrades → higher multiple → sustained trend. That’s why upside persists after the first spike. PT $5.50. Vanguard positioned early with 1,049,265 shares (13F, +131% q/q).

1 · Reply

Market Cap	123.15M
Revenue (ttm)	1.02M
Net Income (ttm)	-18.46M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,809.80%
Debt to Equity Ratio	0.00

Volume	15,300
Avg Vol	6,020
Day's Range	N/A - N/A
Shares Out	3.94M
Stochastic %K	79%
Beta	0.66
Analysts	Sell
Price Target	$35.50